↓ Skip to main content

Dove Medical Press

The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, November 2015
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
64 Mendeley
Title
The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD
Published in
International Journal of Chronic Obstructive Pulmonary Disease, November 2015
DOI 10.2147/copd.s93375
Pubmed ID
Authors

Alberto Papi, Paul W Jones, Prashant S Dalvi, Kirsten McAulay, Tammy McIver, Sanjeeva Dissanayake

Abstract

Inhaled corticosteroid/long-acting β2-agonist combination therapy is recommended in chronic obstructive pulmonary disease (COPD) patients at high risk of exacerbations. The EFFECT (Efficacy of Fluticasone propionate/FormotErol in COPD Treatment) trial is a Phase III, 52-week, randomized, double-blind study to evaluate the efficacy and safety of two doses of fluticasone propionate/formoterol compared to formoterol monotherapy in COPD patients with FEV1 ≥50% predicted and a history of exacerbations. The primary endpoint is the annualized rate of moderate and severe exacerbations. Secondary endpoints include pre-dose FEV1, EXACT-PRO (EXAcerbations of Chronic pulmonary disease Tool - Patient-Reported Outcome)-defined exacerbations, St George's Respiratory Questionnaire for COPD, COPD Assessment Test, and EXACT-Respiratory Symptoms total score. Lung-specific biomarkers (surfactant protein D and CC chemokine ligand-18) will be measured in a subset of patients to explore their relationship to other clinical indices in COPD and their predictive utility. Pneumonia will be diagnosed per criteria defined by the British Thoracic Society community acquired pneumonia guideline, primarily by radiological confirmation and, additionally, using clinical criteria when a chest radiograph cannot be obtained. Serial measurements of serum potassium, vital signs and electrocardiograms, 24-hour Holter monitoring, and 24-hour urinary cortisol measurement will be performed in a subset of patients in addition to conventional safety assessments.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Unknown 63 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 12 19%
Researcher 9 14%
Student > Master 9 14%
Other 8 13%
Student > Ph. D. Student 5 8%
Other 12 19%
Unknown 9 14%
Readers by discipline Count As %
Medicine and Dentistry 31 48%
Nursing and Health Professions 6 9%
Biochemistry, Genetics and Molecular Biology 3 5%
Psychology 3 5%
Pharmacology, Toxicology and Pharmaceutical Science 3 5%
Other 9 14%
Unknown 9 14%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 December 2015.
All research outputs
#19,944,091
of 25,373,627 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#1,937
of 2,577 outputs
Outputs of similar age
#201,825
of 294,811 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#46
of 64 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,577 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 294,811 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 64 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.